Eli Lilly and the Menarini Group have both gotten the nod from the US Food and Drug Administration (FDA) for their new cancer medications. Lilly's therapeutic for relapsed or refractory mantle cell lymphoma, called Jaypirca, is only the fourth drug of its kind approved by the agency. It will cost $21,000 per month of treatment.
According to Ned Pagliarulo, “Menarini's treatment, called Orserdu, is also the newest member of an established drug class, becoming the first oral treatment that works by selectively degrading estrogen receptors. The FDA approved it for postmenopausal women or adult men who have advanced or metastatic breast cancer that's estrogen receptor positive but negative for a protein called HER2. Eligible patients must have tried at least one prior endocrine therapy and seen their cancer progress.”
To read more, click here.
(Source: BioPharmaDive, January 30th, 2023)